March 31, 2009
The current longitudinal study characterized the impact of adherence on survival in treatment-na?ve patients initiating currently recommended highly active antiretroviral therapy (HAART) regimens.
The study focused on 903 patients who had initiated HAART between January 2000 and November 2004, following them until November 2005. The HAART regimens contained efavirenz, nevirapine, or ritonavir-boosted atazanavir or lopinavir.
Among the study participants, all-cause mortality was 11 percent, and individual adherence significantly decreased over the study period. The mean adherence level declined from 79 percent within the first six months after initiating HAART to 72 percent in the 24- to 30-month period (P value
"Incomplete adherence to modern HAART over time was strongly associated with increased mortality, and patients on efavirenz-based NNRTI therapies were particularly at a higher risk if non-adherent," the study authors concluded. "These results highlight the need to develop further strategies to help sustain high levels of adherence on a long-term basis."
04.2009; Vol. 50; No. 5: P. 529-536; Viviane D. Lima, PhD; Richard Harrigan, PhD; David R. Bangsberg, MD, MPH; Robert S. Hogg, PhD; Robert Gross, MD, MSCE; Benita Yip, BSc (Pharm); Julio S.G. Montaner, MD, FRCPC, FCCP
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.